Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

<h4>Background</h4>In breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use. Identification of markers that could predict the response to a particular regimen would thus be critically important for patient care. In cell lines...

Full description

Bibliographic Details
Main Authors: Philippe Bertheau, Elisabeth Turpin, David S Rickman, Marc Espié, Aurélien de Reyniès, Jean-Paul Feugeas, Louis-François Plassa, Hany Soliman, Mariana Varna, Anne de Roquancourt, Jacqueline Lehmann-Che, Yves Beuzard, Michel Marty, Jean-Louis Misset, Anne Janin, Hugues de Thé
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2007-03-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.0040090

Internet

https://doi.org/10.1371/journal.pmed.0040090

Similar Items